No one stays on top forever. It’s a lesson that Ozempic maker Novo Nordisk may be painfully learning about. The Danish ...

The pharma giant has almost doubled the size of its workforce over the last five years but is now looking to tighten cost ...

Novo Nordisk shares climbed after the U.S. Food and Drug Administration approved a new indication for the Danish drugmaker’s ...

Wegovy-maker Novo Nordisk has implemented a global hiring freeze covering job roles that are not critical for its business, ...

Novo Nordisk is slashing the price of its blockbuster diabetes drug Ozempic for U.S. patients who self-pay or are uninsured.

Shares of Novo Nordisk ( NVO 4.81%), the Danish pharmaceuticals company famed for Ozempic and Wegovy weight loss drugs, ...

Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...

Wegovy is now the second medicine approved in the U.S. for a disease that affects millions. Novo Nordisk has several other ...

On Saturday, the U.S. Food and Drug Administration (FDA) approved an additional indication for Novo Nordisk A/S’ (NYSE:NVO) ...

The string of negative updates from Novo Nordisk and positive news flow from the main competitor Eli Lilly has finally ended ...

Novo Nordisk's blockbuster weight-loss drug, Wegovy, received Food and Drug Administration approval to treat a serious ...

With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...